{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:40:43Z","timestamp":1791574843850,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Global Health"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12992-018-0431-0","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T10:27:13Z","timestamp":1542364033000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences"],"prefix":"10.1186","volume":"14","author":[{"given":"H. Hilda","family":"Ampadu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarno","family":"Hoekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Arhinful","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Amoama-Dapaah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert G. M.","family":"Leufkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex N. O.","family":"Dodoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"issue":"8","key":"431_CR1","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2165\/11536390-000000000-00000","volume":"33","author":"S Olsson","year":"2010","unstructured":"Olsson S, Pal SN, Stergachis A, Couper M. Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf. 2010;33(8):689\u2013703.","journal-title":"Drug Saf"},{"key":"431_CR2","first-page":"1","volume":"3","author":"Y Lu","year":"2011","unstructured":"Lu Y, Hernandez P, Abegunde D, Edejer T. The world medicines situation 2011 - medicine expenditures. World Health Organ. 2011;3:1\u201334.","journal-title":"World Health Organ"},{"issue":"1","key":"431_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5530\/ijopp.8.1.2","volume":"8","author":"VV Janarthanan","year":"2015","unstructured":"Janarthanan VV, Ramakrishnan G, Krishnamurthy S, Sahar AI. Pharmacist as pharmacovigilance practitioner. Indian J Pharm Pract. 2015;8(1):2\u20136.","journal-title":"Indian J Pharm Pract"},{"issue":"7","key":"431_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11532410-000000000-00000","volume":"33","author":"J Venulet","year":"2010","unstructured":"Venulet J, Helling-Borda M. WHOs international drug monitoring the formative years, 19681975: preparatory, pilot and early operational phases. Drug Saf. 2010;33(7):1\u201323.","journal-title":"Drug Saf"},{"issue":"4","key":"431_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4103\/0976-500X.85945","volume":"2","author":"M Chakrabarty","year":"2011","unstructured":"Chakrabarty M, Thawani V. Starting a pharmacovigilance center: actions for implementation. J Pharmacol Pharmacother. 2011;2(4):295\u20139.","journal-title":"J Pharmacol Pharmacother"},{"key":"431_CR6","unstructured":"Management Sciences for Health. Assessment of pharmacovigilance systems and their performance. Arlington: 2011; MSH. \n                    http:\/\/apps.who.int\/medicinedocs\/en\/d\/Js19152en\n                    \n                  . Accessed 14 July 2017."},{"key":"431_CR7","volume-title":"Minimum requirements for a functional pharmacovigilance system","author":"World Health Organization","year":"2010","unstructured":"World Health Organization. Minimum requirements for a functional pharmacovigilance system. 2010. \n                    http:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/PV_Minimum_Requirements_2010_2_en.pdf\n                    \n                  . Accessed 14 July 2017."},{"key":"431_CR8","unstructured":"Pal SN, Dodoo A, Mantel A, Olsson S. The world medicines situation. Geneva: WHO; 2011. \n                    http:\/\/apps.who.int\/medicinedocs\/documents\/s18771en\/s18771en.pdf.1\n                    \n                  . Accessed 16 July 2017."},{"issue":"5","key":"431_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.15171\/ijhpm.2015.55","volume":"4","author":"K Maigetter","year":"2015","unstructured":"Maigetter K, Pollock AM, Kadam A, Ward K, Weiss MG. Pharmacovigilance in India, Uganda and South Africa with reference to WHO\u2019s minimum requirements. Int J Health Policy Manag. 2015;4(5):295\u2013305.","journal-title":"Int J Health Policy Manag"},{"issue":"4","key":"431_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1586\/17512433.2015.1053391","volume":"8","author":"S Olsson","year":"2015","unstructured":"Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol. 2015;8(4):449\u201360.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"431_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2042098611425695","volume":"3","author":"AO Isah","year":"2012","unstructured":"Isah AO, Pal SN, Olsson S, Dodoo A, Bencheikh RS. Specific features of medicines safety and pharmacovigilance in Africa. Ther Adv Drug Saf. 2012;3(1):25\u201334.","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"431_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1475-2875-9-148","volume":"9","author":"A Stergachis","year":"2010","unstructured":"Stergachis A, Bartlein RJK, Dodoo A, Nwokike J, Kachur SP. A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President\u2019s Malaria Initiative proposals. Malar J. 2010;9(1):148.","journal-title":"Malar J"},{"issue":"11\/12","key":"431_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1024\/0040-5930\/a000746","volume":"72","author":"M Sch\u00e4ublin","year":"2015","unstructured":"Sch\u00e4ublin M. Pharmacovigiance: the spontaneous reporting system in Switzerland. Ther Umsch. 2015;72(11\/12):743\u20138.","journal-title":"Ther Umsch"},{"key":"431_CR14","first-page":"1","volume-title":"Public Health Act, 2012","author":"The Parliament of the Republic of Ghana","year":"2012","unstructured":"The Parliament of the Republic of Ghana. Public Health Act, 2012; 2012. p. 1\u2013194. \n                    http:\/\/extwprlegs1.fao.org\/docs\/pdf\/gha136559.pdf\n                    \n                  . Accessed 14 July 2017"},{"key":"431_CR15","volume-title":"Understanding the role of Regional Centres of Regulatory Excellence in strengthening medicines regulation in Africa","author":"NEPAD, PATH","year":"2014","unstructured":"NEPAD, PATH. Understanding the role of Regional Centres of Regulatory Excellence in strengthening medicines regulation in Africa. 2014. \n                    http:\/\/www.nepad.org\/resource\/understanding-role-regional-centres-regulatory-excellence-strengthening-medicines\n                    \n                  . Accessed 14 Apr 2017."},{"key":"431_CR16","volume-title":"The Importance of Pharmacovigilance - Safety Monitoring of medicinal products","author":"World Health Organization","year":"2002","unstructured":"World Health Organization. The Importance of Pharmacovigilance - Safety Monitoring of medicinal products. 2002. \n                    http:\/\/apps.who.int\/medicinedocs\/pdf\/s4893e\/s4893e.pdf\n                    \n                  . Accessed 14 Apr 2017."},{"key":"431_CR17","unstructured":"NAFDAC. Nigerian National Pharmacovigilance Policy and Implementation framework. 2012. \n                    https:\/\/drive.google.com\/file\/d\/0B1DAmtM1BcbMX3lqemU4bEtxVW8\/view\n                    \n                  . Accessed 16 July 2017."},{"key":"431_CR18","unstructured":"World Health Organisation. Pharmacovigilance in public health programmes. Geneva; WHO. \n                    http:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/pharmpubhealth\/en\/\n                    \n                  . Accessed 3 Mar 2017."},{"key":"431_CR19","doi-asserted-by":"crossref","unstructured":"Miller V, Nwokike J, Stergachis A. Pharmacovigilance and global HIV \/ AIDS. Curr Opin HIV AIDS. 2012; \n                    https:\/\/journals.lww.com\/co-hivandaids\/Fulltext\/2012\/07000\/Pharmacovigilance_and_global_HIV_AIDS.4.aspx\n                    \n                  . Accessed 16 July 2017.","DOI":"10.1097\/COH.0b013e328354d8e7"},{"issue":"1","key":"431_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-015-1044-1","volume":"15","author":"A Adjei","year":"2016","unstructured":"Adjei A, Narh-Bana S, Amu A, Kukula V, Nagai RA, Owusu-Agyei S, et al. Treatment outcomes in a safety observational study of dihydroartemisinin\/piperaquine (Eurartesim\u00ae) in the treatment of uncomplicated malaria at public health facilities in four African countries. Malar J. 2016;15(1):1\u201310.","journal-title":"Malar J"},{"issue":"7618","key":"431_CR21","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1136\/bmj.39323.586123.BE","volume":"335","author":"M Pirmohamed","year":"2007","unstructured":"Pirmohamed M, Atuah KN, Dodoo ANO, Winstanley P. Pharmacovigilance in developing countries. BMJ. 2007;335(7618):462.","journal-title":"BMJ"},{"key":"431_CR22","unstructured":"GHS-ERC. Ghana Health Service- Ethics Review Committee: Standard Operating Procedures 2015. \n                    https:\/\/www.ghanahealthservice.org\/downloads\/Standard_Operating_Procedures.pdf\n                    \n                  . Accessed 16 June 2018."},{"issue":"1","key":"431_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12992-017-0232-x","volume":"13","author":"K Moscou","year":"2017","unstructured":"Moscou K, Kohler JC. Matching safety to access: global actors and pharmacogovernance in Kenya- a case study. Glob Health. 2017;13(1):20.","journal-title":"Glob Health"},{"issue":"4","key":"431_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40264-015-0387-4","volume":"39","author":"HH Ampadu","year":"2016","unstructured":"Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, et al. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase\u00ae. Drug Saf. 2016;39(4):335\u201345.","journal-title":"Drug Saf"},{"key":"431_CR25","first-page":"924","volume":"33","author":"A Dodoo","year":"2010","unstructured":"Dodoo A, Pal SN, Falzon D, Xueref S. Pharmacovigilance for tuberculosis does not feature prominently in grant applications to the Global Fund to Fight AIDS, tuberculosis and malaria. Drug Saf. 2010;33:924.","journal-title":"Drug Saf"},{"key":"431_CR26","unstructured":"Health Organization W. Pharmacovigilance in public health programmes [internet]. World Health Organization; 2010. \n                    http:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/pharmpubhealth\/en\/\n                    \n                  . Accessed 16 July 2017."},{"key":"431_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/004947550203200101","volume-title":"Gains and losses for Tropical Doctor","author":"M Jones","year":"2002","unstructured":"Jones M. Gains and losses for Tropical Doctor. 2002. \n                    http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/004947550203200101\n                    \n                  . Accessed 06 July 2017."},{"key":"431_CR28","doi-asserted-by":"crossref","unstructured":"Gautam CS, Utreja A, Singal GL. Spurious and counterfeit drugs: a growing industry in the developing world spurious and counterfeit drugs: a growing industry in the developing world. Postgrad Med J. 2009; \n                    http:\/\/pmj.bmj.com\/content\/85\/1003\/251.abstract\n                    \n                  . Accessed 06 July 2017.","DOI":"10.1136\/pgmj.2008.073213"},{"key":"431_CR29","unstructured":"Pisani E, WHO Secretariat. WHO Global Surveillance and Monitoring System for substandard and falsified medical products. World Health Organization; 2017. \n                    http:\/\/www.who.int\/medicines\/regulation\/ssffc\/publications\/GSMS_Report.pdf?ua=1\n                    \n                  . Accessed 16 July 2017."},{"key":"431_CR30","unstructured":"Newton PN, Green MD, Fern\u00e1ndez FM. Impact of poor-quality medicines in the \u2018developing\u2019 world. Trends Pharmacol Sci. 2010. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2845817\n                    \n                  . Accessed 16 July 2017."},{"key":"431_CR31","doi-asserted-by":"publisher","unstructured":"De Bie S, Ferrajolo C, Straus SMJM, Verhamme KMC, Bonhoeffer J, Wong ICK, et al. Pediatric drug safety surveillance in FDA-AERS: a description of adverse events from GRiP project. PLoS One. 2015. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0130399\n                    \n                  . Accessed 16 July 2017.","DOI":"10.1371\/journal.pone.0130399"},{"key":"431_CR32","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40264-018-0677-8","volume":"41","author":"ANO Dodoo","year":"2018","unstructured":"Dodoo ANO. Active safety surveillance in Africa: pragmatism and agility. Drug Saf. 2018;41:731\u20133.","journal-title":"Drug Saf"}],"container-title":["Globalization and Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12992-018-0431-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12992-018-0431-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12992-018-0431-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T19:14:21Z","timestamp":1573845261000},"score":1,"resource":{"primary":{"URL":"https:\/\/globalizationandhealth.biomedcentral.com\/articles\/10.1186\/s12992-018-0431-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["431"],"URL":"https:\/\/doi.org\/10.1186\/s12992-018-0431-0","relation":{},"ISSN":["1744-8603"],"issn-type":[{"value":"1744-8603","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,16]]},"assertion":[{"value":"13 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Per Page 43, Appendix B, Number 2 of the Ghana Health Service Ethics Review Committee\u2019s Standard Operating Procedure, ethical review is not needed for a research that uses interviews to document \u201cpublic behaviour\u201d of professionals working in a public organization and not of patients. All quotes were anonymised to prevent statements being traced back to individuals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"109"}}